Our second Modulating the Tumour Microenvironment conference presents innovations for enhancing the immune anti-tumour response and overcoming inhibitory factors. It is becoming clear that many immunosuppressive mechanisms are at work. The checkpoint inhibitors are not living up to expectations, and for these and other antagonists to be effective, it is necessary to control Tregs and manipulate myeloid-derived and other suppressor cells in the tumour microenvironment (TME). The leaders in the field are also paying attention to the role of cytokines and the importance of Fc-engagement for effective targeting.
THE KEY TO THERAPEUTIC SUCCESS
Using Antibodies to Target the Tumour Microenvironment - Good Intentions Can Often Lead to Unintended Consequences.
Stephen Beers, PhD, Professor, Immunology and Immunotherapy, Centre for Cancer Immunology, Cancer Sciences Unit, University of Southampton
Fc-Dependent Expansion of Distinct Memory Populations Defines the Antitumor Efficacy of Checkpoint Immunotherapy
Jeremy Waight, PhD, Principal Scientist, Immunomodulatory Drug Discovery, Agenus
DEVELOPMENTS WITH IMMUNOCYTOKINES
Development of Novel Immunocytokines for Cancer Immunotherapy
Christian Klein, PhD, Head, Oncology Programs, Head, Cancer Immunotherapy Discovery, Roche Pharmaceutical Research and Early Development (pRED) Roche Innovation Center Zurich
Novel Formats for Antibody-Cytokine Fusion Proteins: Impact on Performance
Dario Neri, PhD, Professor, Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zürich)
Targeted Cytokine Sweeping Activity Using New Bispecific Formats
Marie-Alix Poul, PhD, Professor, Immunology, Biology-Life Science, University of Montpelier, IRCM
TARGETING IMMUNE CHECKPOINTS
Targeting Antibody Checkpoints – Focus on FcγRIIB
Björn Frendéus, PhD, CSO, BioInvent International AB
The Development of KY1043 - A Highly Differentiated PD-L1-Based IL-2Ra Biased Immunocytokine
Matthew McCourt, PhD, VP, Immuno-Oncology, Kymab Ltd.
TARGETING MACROPHAGES AND THE INNATE IMMUNE SYSTEM TO ENHANCE IMMUNOTHERAPY
Targeting Tumor Associated Macrophages to Improve Cancer Immunotherapy
Minhong Yan, PhD, Principal Scientist, Molecular Oncology Genentech, Inc.
Selectively Inhibiting CD47 in the Tumor Microenvironment
Nicolas Fischer, PhD, Head, R&D, Novimmune
TLR Agonist NKTR-262 Immunotherapy Combination with Bempegaldesleukin (NKTR-214) Harnessing Innate and Adaptive Immune System for the Treatment of Solid Tumors
Saul Kivimäe, PhD, Head, in vivo Pharmacology Function, Research Biology, Nektar Therapeutics
FOCUS ON CANCER-SPECIFIC GLYCOFORMS AND GLYCO-IMMUNE CHECKPOINTS
Aberrant Glycosylation in Breast Cancer Results in Modulation of the Immune Microenvironment
Joy Burchell, PhD, Professor, Glyco-oncology, Head, Breast Cancer Biology Lab, Comprehensive Cancer Centre, School of Cancer and Pharmaceutical Sciences, King’s College London
Targeting Immunosuppressive Sialoglycans in the Tumor Microenvironment Using a Novel Therapeutic Modality EAGLE
Li Peng, PhD, SVP, Discovery and Early Product Development, Palleon Pharmaceuticals
* The program is subject to change without notice, due to unforeseen reason.